| NCT05262959 | Shanghai Zhongshan Hospital | Donafenib | 2021-12-01 | PHASE2 |
| NCT03602495 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Differentiated Thyroid Cancer | 2018-08-29 | PHASE3 |
| NCT05576909 | Beijing Tsinghua Chang Gung Hospital|Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Hepatocellular Carcinoma | 2023-03-30 | PHASE2 |
| NCT02870569 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Differentiated Thyroid Cancer | 2016-09 | PHASE2 |
| NCT05493332 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hepatocellular Carcinoma | 2022-09 | PHASE2 |
| NCT05166772 | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 2021-12 | PHASE2 |
| NCT05348811 | Zhongda Hospital | Cholangiocarcinoma | 2022-06-13 | PHASE2 |
| NCT04605185 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unresectable Hepatocellular Carcinoma | 2021-01-08 | PHASE1 |
| NCT04472858 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd|CStone Pharmaceuticals | Advanced Solid Tumor | 2020-10-15 | PHASE1 |
| NCT04503902 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Advanced Hepatocellular Carcinoma | 2020-10-15 | PHASE1|PHASE2 |
| NCT07557914 | Haibo Shao|First Hospital of China Medical University|Liaoning Cancer Hospital & Institute|The General Hospital of Northern Theater Command|The Affiliated Hospital of Yanbian University|Harbin Medical University Third Affiliated Hospital | HCC - Hepatocellular Carcinoma|Diabetes | 2026-04 | PHASE2 |
| NCT04402723 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Acute Myeloid Leukemia (AML) | 2018-11-06 | PHASE1 |
| NCT05507632 | Nanfang Hospital, Southern Medical University | Unresectable Hepatocellular Carcinoma | 2022-08-15 | PHASE2 |
| NCT06609876 | Sun Yat-sen University|Chinese PLA General Hospital | Hepatocellular Carcinoma|Microwave Ablation|Donafenib|Recurrent Tumor | 2024-10-01 | NA |
| NCT05713994 | Ze-yang Ding, MD|Chinese Cooperative Group of Liver Cancer|Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province|Haplox Biotechnology Co., Ltd.|Geneplus-Beijing Co. Ltd.|The Second Affiliated Hospital of Fujian Medical University | Hepatocellular Carcinoma Non-resectable | 2020-05-19 | |
| NCT04418401 | Zhejiang University | Hepatocellular Carcinoma | 2020-06-11 | PHASE1 |
| NCT05545124 | Henan Cancer Hospital | Hepatocellular Carcinoma | 2022-11 | PHASE2 |
| NCT07180459 | Xuhua Duan | Carcinoma|Hepatocellular Carcinoma | 2025-10-10 | |
| NCT02870582 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Metastatic Colorectal Cancer | 2016-12-28 | PHASE3 |
| NCT05138159 | Fudan University | Metastatic Pancreatic Cancer | 2021-12-01 | PHASE2 |
| NCT06239298 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Solid Tumor | 2024-05-10 | PHASE1|PHASE2 |
| NCT07353827 | Sun Yat-sen University | Intrahepatic Cholangiocarcinoma (Icc)|Hepatic Arterial Infusion Chemotherapy | 2026-02-01 | PHASE2 |
| NCT04962958 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Meng Chao Hepatobiliary Hospital of Fujian Medical University|Huashan Hospital|The Second Affiliated Hospital of Harbin Medical University | Carcinoma|Carcinoma, Hepatocellular|Liver Neoplasms|Digestive System Neoplasms|Antineoplastic Agents|Donafenib|Fluorouracil|Oxaliplatin|Antimetabolites | 2023-07-01 | PHASE2 |
| NCT05161143 | Peking Union Medical College Hospital|Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Hepatocellular Carcinoma | 2021-12 | PHASE2 |
| NCT06482086 | West China Hospital | Locally Advanced Thyroid Gland Carcinoma | 2021-06-01 | PHASE2 |
| NCT06581315 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hepatocellular Carcinoma|Adjuvant Therapy | 2024-08-28 | NA |
| NCT02489201 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Oesophageal Cancer | 2015-07-21 | PHASE1|PHASE2 |
| NCT05022628 | Anhui Provincial Hospital | HCC|Chemotherapy Effect | 2021-09-30 | PHASE4 |
| NCT06512467 | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 2024-07-30 | PHASE2 |
| NCT06685289 | The First Affiliated Hospital with Nanjing Medical University | Biliary Malignant Tumors | 2024-11-15 | PHASE2 |
| NCT07157306 | Tianjin Medical University Cancer Institute and Hospital | Hepatocellular Carcinoma | 2025-09-10 | PHASE2 |
| NCT02489214 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Gastric Cancer | 2016-05-16 | PHASE1|PHASE2 |
| NCT06496815 | Tongji Hospital | Unresectable Hepatocellular Carcinoma | 2024-08-01 | PHASE4 |
| NCT06812039 | Fudan University | Hepato Cellular Carcinoma (HCC) | 2025-01-01 | PHASE2 |
| NCT02698111 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Nasopharyngeal Carcinoma | 2017-02-08 | PHASE1|PHASE2 |
| NCT05668884 | Fudan University | Biliary Tract Carcinoma | 2022-10-18 | PHASE2 |
| NCT06498622 | Anhui Provincial Hospital | Hepatocellular Carcinoma | 2024-07-20 | PHASE2 |
| NCT06233994 | Changsha Taihe Hospital | Advanced Hepatocellular Carcinoma | 2024-01 | NA |
| NCT05350943 | Lu Wang, MD, PhD | Biliary Tract Adenocarcinoma | 2022-03-01 | PHASE2 |
| NCT04059874 | First Affiliated Hospital of Zhejiang University | Non-small Cell Lung Cancer | 2019-07-31 | PHASE1 |
| NCT02645981 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Tigermed Consulting Co., Ltd | HCC | 2016-03 | PHASE2|PHASE3 |
| NCT06646198 | Fei Gao | Hepatocellular Carcinoma with PVTT | 2024-10-08 | PHASE2 |
| NCT05310331 | Lei Li | Targeted Therapy|Chemotherapy|Recurrent Cervical Carcinoma|Metastatic Cervical Carcinoma|Persistent Advanced Cervical Carcinoma|Survival Outcomes|Adverse Effect | 2022-03-27 | PHASE2 |
| NCT05205629 | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma|Donafenib | 2022-01-30 | |
| NCT04612712 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd|Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Gastrointestinal Tumors | 2021-01-19 | PHASE1|PHASE2 |